TBE 31 是一种具有口服活性的 Keap1/Nrf2 通路激活剂和 NQO1 诱导剂,对 NQO1 的 Dm 值为 1.1 nM,它通过与 Keap1 半胱氨酸残基结合,抑制 Nrf2 的泛素化与降解,从而激活 ARE 依赖性基因的表达,并可诱导包括 NQO1 和 GST 亚型在内的细胞保护酶,促进 Nrf2 积累,上调受 Nrf2 调控的抗氧化及脂质代谢相关基因,同时抑制促炎反应、AFB1-DNA 加合物形成、内质网应激、细胞凋亡 (apoptosis)、肝纤维化、氧化应激以及 ChREBP 的表达,还能降低紫外线诱导皮肤癌变小鼠模型的肿瘤数量,增强神经生长因子诱导的神经突生长,减弱 LPS 诱导的小鼠血清 TNF-α 水平及不动时间,因此可用于肝癌、皮肤癌、炎症相关抑郁症以及非酒精性脂肪性肝炎的相关研究。
产品编号: MS-T14675 CAS No.: 936475-62-6 分子式: C21H18N2O2 分子量: 330.38
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

TBE 31 是一种具有口服活性的 Keap1/Nrf2 通路激活剂和 NQO1 诱导剂,对 NQO1 的 Dm 值为 1.1 nM,它通过与 Keap1 半胱氨酸残基结合,抑制 Nrf2 的泛素化与降解,从而激活 ARE 依赖性基因的表达,并可诱导包括 NQO1 和 GST 亚型在内的细胞保护酶,促进 Nrf2 积累,上调受 Nrf2 调控的抗氧化及脂质代谢相关基因,同时抑制促炎反应、AFB1-DNA 加合物形成、内质网应激、细胞凋亡 (apoptosis)、肝纤维化、氧化应激以及 ChREBP 的表达,还能降低紫外线诱导皮肤癌变小鼠模型的肿瘤数量,增强神经生长因子诱导的神经突生长,减弱 LPS 诱导的小鼠血清 TNF-α 水平及不动时间,因此可用于肝癌、皮肤癌、炎症相关抑郁症以及非酒精性脂肪性肝炎的相关研究。

生物实验数据

生物活性 TBE 31 is an orally active Keap1/Nrf2 pathway activator and NQO1 inducer with a Dm value of 1.1 nM for NQO1; it binds to Keap1 cysteine residues to inhibit Nrf2 ubiquitination and degradation, thereby activating ARE-dependent gene expression, and it induces cytoprotective enzymes including NQO1 and GST isoforms, promotes Nrf2 accumulation, and upregulates Nrf2-regulated antioxidant and lipid metabolism-related genes, while also inhibiting pro-inflammatory responses, AFB1-DNA adduct formation, endoplasmic reticulum stress, apoptosis, liver fibrosis, oxidative stress, and ChREBP expression, reducing tumor number in a UV-induced skin carcinogenesis mouse model, enhancing nerve growth factor-induced neurite outgrowth, and attenuating LPS-induced serum TNF-α levels and immobility time in mice, and it can therefore be used in research related to liver cancer, skin cancer, inflammation-related depression, and non-alcoholic steatohepatitis.
IC50 & Target

NQO1

 

TNF-α

 

体外研究
(In Vitro)

TBE 31 (48 h) 可在 Hepa1c1c7 细胞中强效诱导 NQO1,其 Dm 值为 1.1 nM。
TBE 31 (0.25-1 μM; 24 h) 可在体外以浓度依赖的方式强效诱导 AREc32 细胞中 ARE 依赖的基因表达。
TBE 31 (0.001-0.1 μM; 24 h) 可在野生型 MEF 细胞中诱导 NQO1,且该诱导作用依赖于转录因子 Nrf2。
TBE-31 可与还原型二硫苏糖醇中的巯基以及重组 Keap1 的半胱氨酸传感器发生可逆结合。
TBE-31 (0.001-0.1 µM; 4 days) 可在体外以浓度依赖的方式增强神经生长因子诱导的 PC12 细胞轴突生长,在孵育 4 天后的 0.1 µM 剂量下达到对照组水平的约 300%。
TBE-31 (0.1 µM) 可上调 Nrf2 蛋白水平,并通过 Nrf2 依赖型机制增强神经生长因子诱导的 PC12 细胞轴突生长。

体内研究
(In Vivo)

TBE-31 (0.03-0.3 μM;局部给药;每 24 小时 1 次;共给药 3 次) 可在健康 SKH-1 无毛小鼠中剂量依赖性地诱导皮肤 NQO1 活性升高至 4.9 倍,GST 活性升高至 1.5 倍。
TBE-31 (按每 3 g 饲料添加 0.1-0.3 μM;口服;每日一次;持续 11 天) 可剂量依赖性地诱导健康 SKH-1 无毛小鼠的肝脏、皮肤和胃 (而非大脑皮层) 中细胞保护酶的活性和蛋白水平升高至最高 5.0 倍,且无毒性。
TBE-31 (10 μM/kg;口服;单次给药) 可使雌性 C57BL/6 小鼠肝脏 NQO1 活性升高 2.4 倍,心脏 NQO1 活性升高 1.5 倍。
TBE-31 (每只动物 40 nM;局部给药;每周 2 次;约 30 周) 可显著降低同时接受 Azathioprine (MS-M69029) 免疫抑制的紫外线诱导皮肤癌变小鼠模型的肿瘤数量与负荷。
TBE-31 (1-10 mg/kg;口服;单次给药) 可对 LPS (MS-X54539) 诱导的 TNF-α 升高发挥剂量依赖性抗炎作用,且在 10 mg/kg 剂量下可显著改善 LPS 处理小鼠的抑郁样行为。
TBE-31 (5 nM/g;口服;每周 3 次;持续 6 周) 处理可逆转饮食诱导的已发病 Nrf2+/+ 小鼠的胰岛素抵抗,减轻肝脏脂肪变性,并改善非酒精性脂肪性肝炎 (NASH) 和肝纤维化;NAS 降低 40.8%,同时糖稳态、氧化应激及炎症标志物均得到改善。
TBE-31 (5 nM/g;口服;每周 3 次;持续 6 周) 需要功能性 Nrf2 才能改善已建立饮食诱导疾病小鼠的胰岛素敏感性、减轻肝脂肪变性并缓解 NASH,因为在 Nrf2-/- 小鼠中这些有益作用完全消失,而 Nrf2+/+ 小鼠的 NAS 降低了 52.9%。

Animal Model: SKH-1 hairless (female, 10-12 weeks old)
Dosage: 0.03 μM; 0.1 μM; 0.3 μM
Administration: topical; every 24 h; 3 doses
Result: Elevated NQO1 specific activity 3.5-fold (0.03 μmol dose), 4.2-fold (0.1 μM dose), and 4.9-fold (0.3 μM dose) compared to control.
Elevated GST specific activity 1.3-fold (0.03 μmol dose), 1.5-fold (0.1 μM dose), and 1.5-fold (0.3 μM dose) compared to control.
Induced statistically significant enzyme activity increases.
Animal Model: SKH-1 hairless (10-12 weeks old)
Dosage: 0.1 μM/3 g diet; 0.3 μM/3 g diet
Administration: oral; daily; 11 days
Result: Increased liver NQO1 activity 2.4-fold (0.1 μM dose) and 3.5-fold (0.3 μM dose); increased liver GST activity 2.4-fold (0.1 μM dose) and 3.7-fold (0.3 μM dose); increased liver GSTA1 protein levels 1.4-fold (0.1 μM dose) and 1.7-fold (0.3 μM dose); increased liver GSTM1 protein levels 1.6-fold (0.1 μM dose) and 1.9-fold (0.3 μM dose); increased liver GSTP1 protein levels 2.2-fold (0.1 μM dose) and 3.6-fold (0.3 μM dose).
Increased skin NQO1 activity 2.2-fold (0.1 μM dose) and 3.5-fold (0.3 μM dose); increased skin GST activity 1.3-fold (0.1 μM dose) and 2.0-fold (0.3 μM dose).
Increased stomach NQO1 activity 3.8-fold (0.1 μM dose) and 4.5-fold (0.3 μM dose); increased stomach GST activity 3.5-fold (0.1 μM dose) and 5.0-fold (0.3 μM dose); increased stomach GSTA1 protein levels 2.2-fold (0.1 μM dose) and 2.4-fold (0.3 μM dose); increased stomach GSTM1 protein levels 2.4-fold (0.1 μM dose) and 3.3-fold (0.3 μM dose); increased stomach GSTP1 protein levels 2.3-fold (0.1 μM dose) and 3.0-fold (0.3 μM dose).
Induced statistically significant enzyme activity and protein level increases.
Caused no observed toxicity.
Showed no changes in cerebral cortex cytoprotective enzyme activities or protein levels.
Animal Model: C57BL/6 (female, 6-12 weeks of age)
Dosage: 10 μM/kg
Administration: p.o.; single dose
Result: Increased hepatic NAD(P)H:quinone oxidoreductase 1 (NQO1) specific enzyme activity 2.4-fold compared to vehicle-treated controls.
Increased cardiac NQO1 specific enzyme activity 1.5-fold compared to vehicle-treated controls.
Animal Model: SKH-1 hairless
Dosage: 40 nM per animal
Administration: topical; twice weekly; ~30 weeks
Result: Dramatically reduced tumor multiplicity and burden compared to controls.
Animal Model: C57BL/6N (adult male, 20-26 g, LPS-induced inflammation-associated depression-like behavior)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: p.o.; single dose
Result: Attenuated LPS-induced increases in serum TNF-α levels in a dose-dependent manner, with the 10 mg/kg dose reaching statistical significance.
Did not alter spontaneous locomotion in LPS-treated mice at 10 mg/kg.
Significantly reduced LPS-induced increases in immobility time in the TST and FST at 10 mg/kg compared to LPS-only treated mice.
Did not affect immobility time in control mice when administered alone.
Animal Model: C57BL/6 wild-type (Nrf2+/+) (male, 8-10 weeks of age, fed sequential high-fat plus 55% fructose (HF55Fr) diet for 15 weeks followed by high-fat plus 30% fructose (HF30Fr) diet for 9 weeks to induce NASH and insulin resistance)
Dosage: 5 nM/g body weight
Administration: p.o.; 3 times weekly; 6 weeks
Result: Enhanced glucose clearance during ITT and GTT, and reduced hepatic gluconeogenesis during PTT compared to vehicle controls.
Decreased post-intervention weight gain, fasted plasma insulin, plasma cholesterol, and plasma alanine aminotransferase activity relative to vehicle-treated HF-fed mice.
Decreased liver triglyceride and cholesterol levels, reduced mRNA expression of Adrp, increased hepatic mRNA for lipid catabolism genes (Acox2, Ces1g, Acot7, Ppara, Cpt1a, Scad), decreased expression of lipogenic transcription factors (Srebf1, Mlxipl, Lxra, Xbp1s) and their target lipid synthesis enzymes (Acaca, Acly, Fasn, Scd1, Dgat2, Lipin1, Mgpat), and increased mRNA for lipid export genes (Mttp, ApoB).
Reduced hepatic protein levels of Bip, phospho-Ire1α, Xbp1s, phospho-eIf2α, and Atf4, and decreased mRNA for Atf4 and Chop relative to vehicle controls.
Attenuated nuclear accumulation of NF-κB p65, p52, p50; increased IκBα protein; decreased phospho-IKKα/β and phospho-JNK; and reduced mRNA for proinflammatory genes (Cox2, Nos2, Il1β, Ifng, Tnfa, Mcp1, Elastase, Mpo) relative to vehicle controls.
Reduced cleavage of Parp, caspase-9, and caspase-3; increased Bcl-2 mRNA; and decreased mRNA for Tgfβ, Col1a1, and α-Sma relative to vehicle controls.
Decreased hepatic malondialdehyde and protein carbonyl levels, increased GSH/GSSG ratio, and induced mRNA for antioxidant Nrf2-target genes (Gclc, Gclm, Gpx2, Nqo1, Gstm1, Hmox1, Txn1, Txnrd1, Slc7a11, Cat, Prdx6) relative to vehicle controls.
Reduced NAFLD Activity Score (NAS) from 4.9 to 2.9, with significant decreases in hepatocyte ballooning and fibrosis relative to vehicle controls.
Animal Model: C57BL/6 wild-type (Nrf2+/+) and Nrf2-knockout (Nrf2-/-) (male, 8-10 weeks of age, fed high-fat plus 30% fructose (HF30Fr) diet for 10 weeks to induce NASH and insulin resistance)
Dosage: 5 nM/g body weight
Administration: p.o.; 3 times weekly; 6 weeks
Result: Enhanced insulin sensitivity during ITT and reduced hepatic gluconeogenesis during PTT compared to vehicle controls in Nrf2+/+ mice.
Reduced weight gain relative to vehicle-treated HF-fed mice in Nrf2+/+ mice.
Decreased liver triglyceride and cholesterol levels, reduced mRNA expression of Adrp, suppressed expression of lipogenic transcription factors (Srebf1, Lxra, Xbp1s) and their target lipid synthesis enzymes, and increased mRNA for lipid export genes (Mttp, ApoB) relative to vehicle controls in Nrf2+/+ mice.
Reduced hepatic protein levels of phospho-Ire1α, Xbp1s, p58IPK, phospho-eIf2α, and Atf4 relative to vehicle controls in Nrf2+/+ mice.
Attenuated nuclear accumulation of NF-κB p65 and p50, and reduced mRNA for Cox2 and Nos2 relative to vehicle controls in Nrf2+/+ mice.
Decreased hepatic malondialdehyde and protein carbonyl levels, and increased GSH/GSSG ratio relative to vehicle controls in Nrf2+/+ mice.
Reduced NAFLD Activity Score (NAS) from 2.125 to 1.0, with decreased steatosis and fibrosis relative to vehicle controls in Nrf2+/+ mice.
Showed no improvement in glucose homeostasis, weight gain, liver steatosis, ER stress, inflammation, oxidative stress, or liver histology relative to vehicle controls in Nrf2-/- mice; did not reduce liver triglyceride/cholesterol levels, suppress lipogenic gene expression, or mitigate NAS in Nrf2-/- mice.

化学信息

分子量 330.38
分子式 C21H18N2O2
CAS No. 936475-62-6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础